Table 1.
Baseline characteristics of the study subjects*
| Characteristic | Ezetimibe add- on group (n = 23) | Increased rosuvastatin (n = 20) |
|---|---|---|
| Age, years† | 56.5 ± 7.4 | 57.0 ± 9.9 |
| Male sex | 22 (95.6) | 17 (85.0) |
| Caucasian | 19 (82.6) | 15 (75.0) |
| Duration of ARV therapy (months)† | 24 (16–34) | 25(14-48) |
| CD4+ cell count (cells/mm3)† | 580.0 ± 193 | 508.0 ± 208 |
| Undetectable VL‡ | 20 (87.0) | 19 (95.0) |
| PI | 21 (91.3) | 17 (85.0) |
| NNRTI | 6 (26.1) | 7 (35.0) |
| NRTI | 23 (100) | 19 (95.0) |
| Fibrate | 4 (17.4) | 6 (30.0) |
| Antihypertensive agents | 13 (56.5) | 6 (30.0) |
| Current Smoker | 6 (26.1) | 1 (5.0) |
| Previous Smoker§ | 8 (34.8) | 14 (70.0) |
| Diabetes Mellitus | 8 (34.8) | 7 (35.0) |
| Hypertension | 13 (56.5) | 6 (30.0) |
| Family History of CVD | 10 (43.5) | 10 (55.0) |
| Body Mass Index (kg/m2)† | 26.0 ± 4.2 | 25.3 ± 4.7 |
| Waist Circumference, cm† | 98 ± 13.7 | 93 ± 15.3 |
*Data are frequency (%) unless otherwise indicated
†Data are mean (±SD)
‡ < 40 copies/mL
§ less than one year of smoking cessation prior to study recruitment
ARV, antiretroviral; VL, viral load; PI, protease inhibitor; NNRTI, non-nucleoside
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase; CVD, cardiovascular disease